Atypical Lymphocytes /ALY/ – Why do they matter?

Atypical lymphocytes represent activated T cells responding to infected B cells or other antigen-presenting cells. Their presence is a hallmark finding in infectious mononucleosis but can also be seen in other viral infections, some bacterial infections, drug reactions, and autoimmune disorders. In automated hematology analyzers, they may be flagged as variant lymphocytes or atypical lympho (ALY) populations.  Quantification is usually performed by manual differential count on a stained peripheral blood smear.

Clinically, a high proportion of atypical lymphocytes supports a reactive process rather than a lymphoproliferative malignancy, although correlation with clinical and laboratory data is essential. Persistent or very high counts may require further evaluation to exclude hematologic neoplasms.

Atypical lymphocytes are a morphological indicator of immune activation, most commonly associated with viral infections. A high proportion in peripheral blood strongly supports the diagnosis of infectious mononucleosis caused by the Epstein–Barr virus, particularly when typical clinical symptoms are present. They are also observed in Cytomegalovirus infections and other systemic viral diseases.

Their presence helps differentiate reactive lymphocytosis from clonal lymphoproliferative disorders, reducing the risk of misdiagnosis. Although automated analyzers may generate suspect flags, microscopic verification remains essential.

A threshold of ≥10% atypical lymphocytes increases diagnostic specificity for infectious mononucleosis in the appropriate clinical context. However, persistent or unexplained atypical lymphocytosis requires further evaluation to exclude hematologic malignancies.

However, persistent or unexplained atypical lymphocytosis requires further evaluation using immunophenotyping and molecular studies to exclude hematologic malignancies.

Therefore, atypical lymphocytes serve as a valuable, cost-effective diagnostic clue that must always be interpreted in conjunction with clinical findings and additional laboratory tests.

Thanks to the advanced capabilities of our hematology analyzers, Mythic 60 and Mythic 70, laboratories can detect and report atypical lymphocyte (ALY) populations.

Their multi-patented technology, combined with features such as dynamic clustering, provides comprehensive information about patient health. The ALY parameter offers additional insight, supporting faster diagnosis, disease management, and prognosis assessment.

Check out our hematology solutions

References:

<sub>1. Bain, B. J. Blood Cells: A Practical Guide, 5th ed., Wiley-Blackwell, 2015.
2. World Health Organization. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th ed., IARC, 2017.
3. McKenzie, S. B., Williams, J. L. Clinical Laboratory Hematology, 3rd ed., Pearson, 2015.
4. Henry, J. B. Clinical Diagnosis and Management by Laboratory Methods, 23rd ed., Elsevier, 2017.
5. Shiftan, T. A., Mendelsohn, J. “The circulating atypical lymphocyte.” Human Pathology, 1978;9(1):51–61.
6. Wood, T. A., Frenkel, E. P. “The atypical lymphocyte.” Hematology & Oncology, University of Texas Southwestern Medical Center.
7. Lv, J., Gao, M., Zong, H., et al. “Application of peripheral blood lymphocyte count in prediction of the presence of atypical lymphocytes.” Clinical Laboratory, 2020.
8. Kim, T.-S., Kim, H. K., Kim, S. Y., Chang, Y. H. “Atypical lymphocytosis induced by T-cell-engaging therapy in patients with hematological malignancies.” International Journal of Laboratory Hematology, 2026.
9. American Society of Hematology. “A hematopathologist’s approach to atypical lymphocytosis.” The Hematologist.
10. HORIBA Medical. “Atypical lymphocytes – clinical significance and associated conditions.”</sub>